Advertisement


Julie Vose, MD, MBA, and Mhairi Copland, MB, ChB, PhD, on CML: Data From the British DESTINY Study

2016 ASH Annual Meeting & Exposition

Advertisement

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Mhairi Copland, MB, ChB, PhD, of the Paul O’Gorman Leukaemia Research Centre at the University of Glasgow, discuss decreasing the dose of tyrosine kinase inhibitors in CML patients with stable molecular responses (Abstract 938).



Related Videos

Hematologic Malignancies
Issues in Oncology

Marie Bleakley, MD, PhD, on GVHD: Reducing Rates and Increasing Survival

Marie Bleakley, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses data on using naive T-cell depletion of peripheral blood stem cells, which led to very low rates of chronic graft-vs-host-disease and high survival (Abstract 668).

Leukemia

Terry J. Fry, MD, on ALL: MRD and CAR Therapy

Terry J. Fry, MD, of the Pediatric Oncology Branch of the National Cancer Institute, discusses minimal residual disease–negative complete remissions following anti-CD22 chimeric antigen receptor in children and young adults with relapsed/refractory acute lymphoblastic leukemia (Abstract 650).

Lymphoma

Robert E. Marcus, MD, on Follicular Lymphoma: Results From the GALLIUM Trial

Robert E. Marcus, MD, of Kings College Hospital, discusses study findings on obinutuzumab-based induction and maintenance in patients with previously untreated disease (Abstract 6).

Leukemia

Julie Vose, MD, MBA, and Anjali Advani, MD, on AML: Results of Two Trials on Vadastuximab Talirine

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Anjali Advani, MD, of the Cleveland Clinic, discuss study findings on vadastuximab talirine as monotherapy and, in another trial, vadastuximab talirine plus hypomethylating agents in older patients with AML (Abstracts 590, 591).

Hematologic Malignancies
Symptom Management

Jean M. Connors, MD, and Julie Vose, MD, MBA, on Thrombosis and Anticoagulation: Best of ASH Clinical Data

Jean M. Connors, MD, of Brigham and Women’s Hospital, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss a roundup of key findings on a critical area in the treatment of hematologic malignancies (Abstracts 17, 85, 86, 135, 139, 143, 273, 415, 419, 719, 877, 880).

Advertisement

Advertisement




Advertisement